FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thierry Delozier

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Geographic Areas

France

Co-author Network

Publications

TOP 3
Sabine Noal; Chantal Rieux; Carine Ségura; Odile Switsers; Christelle Levy; Djelila Allouache; Fabienne Collet; Corinne Delcambre; Thierry Delozier; Agnès Hardouin; Michel Henry-Amar; Natacha Heutte; Florence Joly
One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer.
Frédérique Penault-Llorca; Thierry Petit; Marc Spielmann; David Coeffic; Thierry Delozier; Nadine Dohollou; Gilles Freyer; Joseph GLIGOROV; Anne-Claire Hardy-Bessard; William Jacot; Jean-Louis Misset; Jean-Marc Nabholtz; Moïse Namer
[Node negative breast cancer. Beyond international consensus: a pragmatic approach].
Jean-Marc Extra; Eric C Antoine; Anne Vincent-Salomon; Thierry Delozier; Pierre Kerbrat; Anne Bethune-Volters; Jean-Paul Guastalla; Marc Spielmann; Louis Mauriac; Jean-Louis Misset; Daniel Serin; Mario Campone; Christophe Hebert; Céline Remblier; Loïc Bergougnoux; Frank Campana; Moïse Namer
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thierry Delozier (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Sabine Noal; Chantal Rieux; Carine Ségura; Odile Switsers; Christelle Levy; Djelila Allouache; Fabienne Collet; Corinne Delcambre; Thierry Delozier; Agnès Hardouin; Michel Henry-Amar; Natacha Heutte; Florence Joly
One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer.
International journal of radiation oncology, biology, physics 2011;81(3):795-803.
2011: Frédérique Penault-Llorca; Thierry Petit; Marc Spielmann; David Coeffic; Thierry Delozier; Nadine Dohollou; Gilles Freyer; Joseph GLIGOROV; Anne-Claire Hardy-Bessard; William Jacot; Jean-Louis Misset; Jean-Marc Nabholtz; Moïse Namer
[Node negative breast cancer. Beyond international consensus: a pragmatic approach].
Bulletin du cancer 2011;98(7):807-25.
2010: Jean-Marc Extra; Eric C Antoine; Anne Vincent-Salomon; Thierry Delozier; Pierre Kerbrat; Anne Bethune-Volters; Jean-Paul Guastalla; Marc Spielmann; Louis Mauriac; Jean-Louis Misset; Daniel Serin; Mario Campone; Christophe Hebert; Céline Remblier; Loïc Bergougnoux; Frank Campana; Moïse Namer
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
The oncologist 2010;15(8):799-809.
2009: Marc Spielmann; Henri Roché; Thierry Delozier; Jean-Luc Canon; Gilles Romieu; Hugues Bourgeois; Jean-Marc Extra; Daniel Serin; Pierre Kerbrat; Jean-Pascal Machiels; Alain Lortholary; Hubert Orfeuvre; Mario Campone; Anne-Claire Hardy-Bessard; Bruno Coudert; Marie Maerevoet; Gilles Piot; Andrew Kramar; Anne-Laure Martin; Frédérique Penault-Llorca
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(36):6129-34.
2007: Nicolas Aide; Virginie Huchet; Odile Switsers; Natacha Heutte; Thierry Delozier; Agnes Hardouin; Stéphane Bardet
Influence of CA 15-3 blood level and doubling time on diagnostic performances of 18F-FDG PET in breast cancer patients with occult recurrence.
Nuclear medicine communications 2007;28(4):267-72.
2006: Henri Roché; Pierre Fumoleau; Marc Spielmann; Jean-Luc Canon; Thierry Delozier; Daniel Serin; Michel Symann; Pierre Kerbrat; Patrick Soulié; Françoise Eichler; Patrice Viens; Alain Monnier; Anita Vindevoghel; Mario Campone; Marie-Josèphe Goudier; Jacques Bonneterre; Jean-Marc Ferrero; Anne-Laure Martin; Jean Genève; Bernard Asselain
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(36):5664-71.
2006: Thierry Delozier; Jean-Paul Guastalla; Alejandro Yovine; Christelle Levy; Philippe Chollet; Mireille Mousseau; Rémi Delva; David Coeffic; Jean-Michel Vannetzel; Eliette-Sudriez Zazzi; Silvano Brienza; Esteban Cvitkovic
A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
Anti-cancer drugs 2006;17(9):1067-73.
2006: Hugues Bourgeois; Aurélie Ferru; Alain Lortholary; Thierry Delozier; Michèle Boisdron-Celle; Sophie Abadie-Lacourtoisie; Florence Joly; Stéphanie Chieze; Virginie Chabrun; Erick Gamelin; Jean-Marc Tourani
Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
American journal of clinical oncology 2006;29(3):267-75.
2006: A Andrieux; Odile Switsers; M H Chajari; J H Jacob; Thierry Delozier; R Gervais; N Allouache; V Laurençon; Michel Henry-Amar; Stéphane Bardet
Clinical impact of fluorine-18 fluorodeoxyglucose positron emission tomography in cancer patients. A comparative study between dedicated camera and dual-head coincidence gamma camera.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2006;50(1):68-77.
2005: Daniel Serin; M Verrill; A Jones; Thierry Delozier; R Coleman; E-D Kreuser; K Mross; B Longerey; M Brandely
Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.
British journal of cancer 2005;92(11):1989-96.
2005: Rodrigo Arriagada; Monique G Lê; Marc Spielmann; Louis Mauriac; Jacques Bonneterre; Moïse Namer; Thierry Delozier; Catherine Hill; Thomas Tursz
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(3):389-96.
2005: Thierry Delozier
[Hormone therapy in breast cancer: the end of tamoxifen?].
Bulletin du cancer 2005;92(2):142-50.
2005: Rodrigo Arriagada; Marc Spielmann; serge koscielny; Thierry Le Chevalier; Thierry Delozier; Monique Rémé-Saumon; Muriel Ducourtieux; Thomas Tursz; Catherine Hill
Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer.
Acta oncologica (Stockholm, Sweden) 2005;44(5):458-66.
2005: Jean-Pierre Lotz; Hervé Curé; Maud Janvier; Bernard Asselain; François Morvan; Michel Legros; Bruno Audhuy; Pierre Biron; Maryse Guillemot; Jocelyne Goubet; Abderrahmane Laadem; Christian Cailliot; Christine Le Maignan; Thierry Delozier; Sylvie Glaisner; Dominique Maraninchi; Henri Roché; Christian Gisselbrecht
High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol.
European journal of cancer (Oxford, England : 1990) 2005;41(1):71-80.
2004: Jean-Philippe Spano; David Khayat; Thierry Delozier
[Aromatase inhibitors in adjuvant setting in breast cancer].
Bulletin du cancer 2004;91 Suppl 4():S239-43.
2004: Jacques Bonneterre; Véronique Dieras; Michèle Tubiana-Hulin; Philippe Bougnoux; Marie-Edith Bonneterre; Thierry Delozier; F Mayer; Stéphane Culine; N Dohoulou; B Bendahmane
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer.
British journal of cancer 2004;91(8):1466-71.
2004: R Charles Coombes; Emma Hall; Lorna J Gibson; Robert Paridaens; Jacek Jassem; Thierry Delozier; Stephen E Jones; Isabel Alvarez; Gianfilippo Bertelli; Olaf Ortmann; Alan Coates; Emilio Bajetta; David Dodwell; Robert E Coleman; Lesley Fallowfield; Elizabeth Mickiewicz; Jorn Andersen; Per Eystein Lønning; Giorgio Cocconi; Alan Stewart; Nick Stuart; Claire F Snowdon; Marina Carpentieri; Giorgio Massimini; Judith M Bliss; Cornelius van de Velde
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
The New England journal of medicine 2004;350(11):1081-92.
2004: Gilles Freyer; Alain Lortholary; Corinne Delcambre; Thierry Delozier; Gilles Piot; Françoise Genin; Eric Pujade-Lauraine
Unexpected toxicities in elderly patients treated with oral idarubicin in metastatic breast cancer: the GINECO experience.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2004;16(1):17-23.
2004: Jean-Jacques Michels; Jacques Marnay; Thierry Delozier; Yves Denoux; Jacques Chasle
Proliferative activity in primary breast carcinomas is a salient prognostic factor.
Cancer 2004;100(3):455-64.
2003: Jean-Jacques Michels; Françoise Duigou; Jacques Marnay; Yves Denoux; Thierry Delozier; Jacques Chasle
Flow cytometry in primary breast carcinomas: prognostic impact of multiploidy and hypoploidy.
Cytometry. Part B, Clinical cytometry 2003;55(1):37-45.
2003: Jacques Chasle; Thierry Delozier; Yves Denoux; Jacques Marnay; Jean-Jacques Michels
Immunohistochemical study of cell cycle regulatory proteins in intraductal breast carcinomas--a preliminary study.
European journal of cancer (Oxford, England : 1990) 2003;39(10):1363-9.
2003: Alain Lortholary; Thierry Delozier; Alain Monnier; Hugues Bourgeois; Philippe Bougnoux; Nicole Tubiana-Mathieu; J Ch Riffaud; D Besson; V Lotz; Erick Gamelin
Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer.
British journal of cancer 2003;88(11):1669-74.
2003: Jean-Jacques Michels; Françoise Duigou; Jacques Marnay; Michel Henry-Amar; Thierry Delozier; Yves Denoux; Jacques Chasle
Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma: prognostic significance.
Cancer 2003;97(6):1376-86.
2003: Patricia Marino; Anne-Gaelle Le Corroller; Thao Palangié; Maud Janvier; Michel Fabbro; Laurent Molinier; Thierry Delozier; Alain Livartowski; Jean-Paul Moatti; Patrice Viens
Can sequential administration minimise the cost of high dose chemotherapy? An economic assessment in inflammatory breast cancer.
PharmacoEconomics 2003;21(11):807-18.
2003: Gilles Freyer; Thierry Delozier; M Lichinister; D Gedouin; Philippe Bougnoux; P His; K Imadalou; Véronique Trillet-Lenoir
Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(1):35-40.
2002: Michel Héry; Thierry Delozier; Alain Ramaioli; Jean-Pierre Julien; Brigitte de Lafontan; Thierry Petit; Catherine de Ghislain; Béatrice Weber; Jacques Bonneterre; Eric Teissier
Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?
Breast (Edinburgh, Scotland) 2002;11(5):442-8.
2002: Rodrigo Arriagada; Marc Spielmann; serge koscielny; Thierry Le Chevalier; Thierry Delozier; Muriel Ducourtieux; Thomas Tursz; Catherine Hill
Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(9):1378-86.
2001: Alain Depierre; Gilles Freyer; Jacek Jassem; Hubert Orfeuvre; Rodryg Ramlau; E Lemarie; Piotr Koralewski; Louis Mauriac; Jean-Luc Breton; Thierry Delozier; Véronique Trillet-Lenoir
Oral vinorelbine: feasibility and safety profile.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(12):1677-81.
2001: Patrice Viens; Henri Roché; Pierre Kerbrat; P Fumoleau; Jean-Paul Guastalla; Thierry Delozier
Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
American journal of clinical oncology 2001;24(4):328-35.
2001: Moïse Namer; P Soler-Michel; Francois Turpin; P Chinet-Charrot; C de Gislain; Pierre Pouillart; Thierry Delozier; Elisabeth Luporsi; Pierre-Luc Etienne; Simon Schraub; Jean-Christophe Eymard; Daniel Serin; Gérard Ganem; Gilles Calais; P Maillart; P Colin; Véronique Trillet-Lenoir; G Prevost; D Tigaud; Pierre Clavère; P Marti; Gilles Romieu; J L Wendling
Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2001;37(9):1132-40.
2001: Yves Denoux; Jacques Marnay; Hubert Crouet; Véronique Boute; Thierry Delozier; B Vie; Jacques Chasle
[Evaluation of predictive factors, particularly the Van Nuys index, of local recurrence in ductal carcinoma in situ of the breast: study of 166 cases with conservative treatment and review of the literature].
Bulletin du cancer 2001;88(4):419-25.
2001: P Fumoleau; Franck Chauvin; Moïse Namer; R Bugat; Michèle Tubiana-Hulin; Jean-Paul Guastalla; Thierry Delozier; Pierre Kerbrat; Yves Devaux; Jacques Bonneterre; A Filleul; MD Clavel
Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):612-20.
2000: Agnès Laplanche; L Alzieu; Thierry Delozier; J Berlie; Corinne Veyret; Pierre Fargeot; Monique Luboinski; J Lacour
Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC).
Breast cancer research and treatment 2000;64(2):189-91.
2000: Thierry Delozier; Marc Spielmann; J Macé-Lesec'h; Maud Janvier; C Hill; Bernard Asselain; J P Julien; B Weber; Louis Mauriac; J C Petit; Pierre Kerbrat; J P Malhaire; P Vennin; B Leduc; Moïse Namer
Tamoxifen adjuvant treatment duration in early breast cancer: initial results of a randomized study comparing short-term treatment with long-term treatment. Fédération Nationale des Centres de Lutte Contre le Cancer Breast Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3507-12.
2000: Thierry Delozier; Odile Switsers; Jean-Yves Génot; J M Ollivier; Michel Héry; Moïse Namer; M Fresney; Pierre Kerbrat; Corinne Veyret; Brigitte de Lafontan; Maud Janvier; J Macé-Lesech
Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(5):515-9.
2000: Geneviève Macquart-Moulin; Patrice Viens; Thao Palangié; ML Bouscary; Thierry Delozier; Henri Roché; Maud Janvier; Michel Fabbro; Jean-Paul Moatti
High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(4):754-64.
1999: Patrice Viens; Thao Palangié; Maud Janvier; Michel Fabbro; Henri Roché; Thierry Delozier; J P Labat; C Linassier; Bruno Audhuy; F Feuilhade; B Costa; Rémi Delva; Hervé Cure; F Rousseau; A Guillot; Mireille Mousseau; J M Ferrero; V J Bardou; J Jacquemier; Pierre Pouillart
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
British journal of cancer 1999;81(3):449-56.
1997: Thierry Delozier; Odile Switsers; Jean-Yves Génot; J M Ollivier; Michel Héry; Moïse Namer; Marc Frenay; Pierre Kerbrat; J P Julien; A Naja; Maud Janvier; J Macé-Lesec'h
[Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
Bulletin du cancer 1997;84(1):25-30.
1996: PC Clahsen; Cornelis J H van de Velde; J P Julien; J L Floiras; Thierry Delozier; F Y Mignolet; TM Sahmoud
Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):745-53.
1995: Pierre Fumoleau; Thierry Delozier; J M Extra; L Canobbio; F M Delgado; P Hurteloup
Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.
Seminars in oncology 1995;22(2 Suppl 5):22-8; discussion 28-9.
1994: E Garcia-Giralt; C Omodei Zorini; L Ferri; Y Ayme; M Carton; A Daban; Thierry Delozier; Pierre Fargeot; Pierre Fumoleau; A Gorins
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
La Clinica terapeutica 1994;145(8):113-21.
1994: R Pérez Carrión; V Alberola Candel; F Calabresi; R T Michel; R Santos; Thierry Delozier; P Goss; L Mauriac; F Feuilhade; M Freue
Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 7():S19-24.
1993: Pierre Fumoleau; F M Delgado; Thierry Delozier; A Monnier; M A Gil Delgado; P Kerbrat; E Garcia-Giralt; R Keiling; Moïse Namer; M T Closon
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(7):1245-52.
1992: E Garcia-Giralt; Y Ayme; M Carton; A Daban; Thierry Delozier; Pierre Fargeot; Pierre Fumoleau; A Gorins; D Guerin; R Guerin
Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen.
Breast cancer research and treatment 1992;24(2):139-45.
1991: Thierry Delozier; J C Vernhes
[Comparative study of adriamycin, epirubicin and mitoxantrone in cancer of the breast. Review of the literature].
Bulletin du cancer 1991;78(11):1013-25.
1991: J Lacour; A Laplanche; Thierry Delozier; J Berlie; N Mourali; J P Julien; C De Gislain; Moïse Namer; J C Petit; V Denis
Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. A 6 1/2 year follow-up analysis of a randomized trial of the French Federation of Cancer Centers (F.F.C.C.).
Breast cancer research and treatment 1991;19(1):15-21.
1990: M Hery; C Granon; Thierry Delozier; C Degislain; D Horner-Vallet; P Maisse; A Naja; J C Petit; B Weber
[Node negative breast cancers: the good and the bad cases].
Pathologie-biologie 1990;38(8):836-8.
1990: Marc Spielmann; P Kerbrat; Thierry Delozier; Pierre Fumoleau; A Monnier; Bernard Chevallier; P Bastit; Moïse Namer; A Cattan; P Lucas
Pirarubicin in advanced breast cancer: a French cooperative phase II study.
European journal of cancer (Oxford, England : 1990) 1990;26(7):821-3.
1986: Thierry Delozier; J P Julien; P Juret; C Veyret; J E Couëtte; Y Graic; Jean-Marie Ollivier; E de Ranieri
Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial.
Breast cancer research and treatment 1986;7(2):105-9.
1983: E de Ranieri; A M Mandard; P Juret; J E Couette; Thierry Delozier; Jean-Marie Ollivier; G Leplat; F Rault
[Reliability of cytologic puncture. Who should perform the puncture of breast tumors?].
Presse médicale (Paris, France : 1983) 1983;12(24):1527-9.
1982: P Juret; J F Heron; J E Couette; Thierry Delozier; J Y Le Talaer
Hydroxy-9-methyl-2-ellipticinium for osseous metastases from breast cancer: a 5-year experience.
Cancer treatment reports 1982;66(11):1909-16.
1981: P Juret; J E Couette; Thierry Delozier; J Y Le Talaer
[Hydroxy-9-methyl-2-ellipticinium (NSC 264-137) for osseous metastases from breast cancer. A 4 year experience (author's transl)].
Bulletin du cancer 1981;68(3):224-31.
1980: P Juret; J E Couette; Thierry Delozier; G Leplat; L Blanc; A M Mandard; J C Vernhes
[Effect of the sex of the newborn infant on subsequent breast cancer in the mother].
Bulletin de l'Académie nationale de médecine 1980;164(4):353-7.
1980: P Juret; Y Le Talaer; J E Couette; Thierry Delozier
Hydroxy-9-methyl-2-Ellipticinium (NSC 264-137) in 52 cases of osseous metastases from breast cancer.
European journal of cancer 1980;Suppl 1():277-9.